Drug Profile
OC 10X
Alternative Names: OC-10XLatest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator OcuCure Therapeutics
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Tubulin inhibitors; Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Age-related macular degeneration
- Discontinued Diabetic retinopathy
Most Recent Events
- 24 Sep 2021 Discontinued - Phase-II for Diabetic retinopathy in Bangladesh (Ophthalmic)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Age-related-macular-degeneration(In volunteers) in Bangladesh (Ophthalmic, Drops)
- 01 Oct 2016 OcuCure Therapeutics terminates a phase II trial in Diabetic retinopathy in Bangladesh (Ophthalmic) (NCT02735369)